Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Cogane; JNX-1001; PYM-50028; Smilagenin

Latest Information Update: 26 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phytopharm
  • Developer IXICO
  • Class Antidementias; Herbal medicines; Neuroprotectants; Nootropics; Small molecules; Steroid sapogenins
  • Mechanism of Action Brain derived neurotrophic factor agonists; Glial cell line-derived neurotrophic factor agonists; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Alzheimer's disease; Amyotrophic lateral sclerosis; Glaucoma; Parkinson's disease

Most Recent Events

  • 23 May 2013 Phytopharm conducts discussions with external parties for further development of sarsasapogenin under licensing arrangements
  • 28 Feb 2013 Efficacy data from the phase II CONFIDENT-PD trial in Parkinson's disease released by Phytopharm
  • 18 Apr 2012 Pharmacodynamics data from a preclinical trial in Amyotrophic lateral sclerosis released by Phytopharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top